Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer

In this phase-I trial, we evaluated the safety of S-1, a novel oral fluoropyrimidine anticancer agent, combined with external-beam radiotherapy (EBRT) to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) in unresectable pancreatic cancer patients. Patients had histologically prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinchi, H, Maemura, K, Noma, H, Mataki, Y, Aikou, T, Takao, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360168/
https://www.ncbi.nlm.nih.gov/pubmed/17437021
http://dx.doi.org/10.1038/sj.bjc.6603735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360168/
https://www.ncbi.nlm.nih.gov/pubmed/17437021
http://dx.doi.org/10.1038/sj.bjc.6603735

Ejemplares similares